United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 4 minute read Healthcare Industry News CooperCompanies Q2 FY2025 results: Revenue tops $1bn, but stock hits 52-week low Despite 14% EPS growth and a strong lens and surgical portfolio, CooperCompanies stock falls to 52-week low. Find out what’s driving investor sentiment. byPallavi MadhirajuMay 30, 2025